LIPO (Lipella Pharmaceuticals) FCF Margin %: 0.00% (As of Sep. 2025)


What is Lipella Pharmaceuticals FCF Margin %?

Lipella Pharmaceuticals LIPO +8.43% FCF Margin % is 0.00% as of Sep. 2025. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Lipella Pharmaceuticals ranks worse than 78.33% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lipella Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2025 was $-0.93 Mil. Lipella Pharmaceuticals's Revenue for the three months ended in Sep. 2025 was $0.00 Mil. Therefore, Lipella Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2025 was 0.00%.

As of today, Lipella Pharmaceuticals's current FCF Yield % is -1,147.84%.

The historical rank and industry rank for Lipella Pharmaceuticals's FCF Margin % or its related term are showing as below:

LIPO' s FCF Margin % Range Over the Past 10 Years
Min: -995.11   Med: -703.11   Max: -3.01
Current: -890.86

During the past 5 years, the highest FCF Margin % of Lipella Pharmaceuticals was -3.01%. The lowest was -995.11%. And the median was -703.11%.

LIPO's FCF Margin % is ranked worse than
78.33% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs LIPO: -890.86

Lipella Pharmaceuticals FCF Margin % Related Terms

Lipella Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals FCF Margin % Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
-3.01 -381.85 -995.11 -703.11 -737.13

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -184.70 0.00 0.00 0.00

LIPO vs WINT, RMTG, CYTOF: FCF Margin % Comparison

For the Biotechnology subindustry, Lipella Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipella Pharmaceuticals FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's FCF Margin % falls into.


Lipella Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lipella Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-3.951/0.536
=-737.13 %

Lipella Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-0.926/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Lipella Pharmaceuticals (LIPO) has a FCF Margin % of 0.00% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lipella Pharmaceuticals and its competitors. According to the industry distribution chart, Lipella Pharmaceuticals ranks #752 out of 960 companies in the Biotechnology industry, placing it in the top 78.3%.
Is Lipella Pharmaceuticals' FCF Margin % too high?
Lipella Pharmaceuticals' current FCF Margin % is 0.00%. Based on the distribution chart, Lipella Pharmaceuticals ranks #752 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lipella Pharmaceuticals' FCF Margin % compare to WINT and RMTG?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #752 out of 960 companies for FCF Margin %. This places Lipella Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.66, compared to a current price of $0.09 — trading 99% below its estimated fair value. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current FCF Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.